IGC Pharma (IGC) Operating Expenses (2010 - 2025)

IGC Pharma (IGC) has 16 years of Operating Expenses data on file, last reported at $3.0 million in Q3 2025.

• Operating Expenses for Q3 2025 came in at $3.0 million, up 53.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (down 37.3% YoY), and the FY2026 annual result was $2.5 million, down 69.01% from the prior year.
• Operating Expenses improved to $3.0 million in Q3 2025 per IGC's latest filing, from $2.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $6.6 million in Q1 2022 and troughed at $1.6 million in Q1 2025.
• A 5-year average of $2.9 million and a median of $2.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2021 and 2024: Operating Expenses jumped 157.7% in 2021, then slumped 42.82% in 2024.
• A 5-year view of Operating Expenses shows it stood at $2.4 million in 2021, then retreated by 2.74% to $2.4 million in 2022, then surged by 31.55% to $3.1 million in 2023, then tumbled by 36.7% to $2.0 million in 2024, then jumped by 51.26% to $3.0 million in 2025.
• Business Quant data shows IGC's Operating Expenses at $3.0 million in Q3 2025, $2.1 million in Q2 2025, and $1.6 million in Q1 2025.